RE:Sirona Press ReleaseThe ultimate goal for the company is to maximize the value of an exit down the road, hence the emphasis on royalty. I still believe the up-front to be good enough in order to carry the cost of lab expansion, additional employees including Dr Bieber and accelerated pipeline without further dilution. That's the short term idea with the deal.
Don't think we must wait too long before abbvie product launch that will trigger milestones. Abbvie has been in the know for a long time and should've made the advancements even before the deal was made.
I was not happy with the misleading information stated in the previous company update regarding start of clinical trial for anti-aging in September, now they are aiming for an agreement with a parter prior to the trial. On the other hand we can expect a NR revealing the partner very soon.
Additional business opportunity was revealed for TFC-039 in human diabetes. Maybe the potential partner in India has returned, great market. A few years back this company showed interest, but waited for further scientific advancements of the compound and put the deal on hold.
I think the company is on the doorstep for a successful ride. Multiple positive NR should be expected in Q4 and Q1, including the diabetes pet deal.
They have previously indicated that Linda Pullan will be involved again going forward and I trust her to make the most of the deals in terms of business value. I'm here for the anti-aging deal, could be massive!